

**Texas Prior Authorization Program
Clinical Criteria**

Drug/Drug Class

Desmopressin

Clinical Criteria Information Included in this Document

Desmopressin - Oral

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical criteria
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical criteria rules
- **Logic diagram:** a visual depiction of the clinical criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable
- **References:** clinical publications and sources relevant to this clinical criteria

Desmopressin - Injectable

- **Drugs requiring prior authorization:** the list of drugs requiring prior authorization for this clinical criteria
- **Prior authorization criteria logic:** a description of how the prior authorization request will be evaluated against the clinical criteria rules
- **Logic diagram:** a visual depiction of the clinical criteria logic
- **Supporting tables:** a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable
- **References:** clinical publications and sources relevant to this clinical criteria

Note: Click the hyperlink to navigate directly to that section.

Revision Notes

Updated ICD-10 codes for dialysis in supporting table 1 for desmopressin oral agents



**Desmopressin
Oral**
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

| Drugs Requiring Prior Authorization | |
|--|------------|
| Label Name | GCN |
| DDAVP 0.1 MG TABLET | 26171 |
| DDAVP 0.2 MG TABLET | 26172 |
| DESMOPRESSIN ACETATE 0.1 MG TB | 26171 |
| DESMOPRESSIN ACETATE 0.2 MG TB | 26172 |




Desmopressin
Oral
Clinical Criteria Logic

1. Does the client have a diagnosis of **moderate to severe renal impairment** in the last 365 days?
[] Yes (Deny)
[] No (Go to #2)
2. Does the client have a diagnosis of **primary nocturnal enuresis or diabetes insipidus** in the last 730 days?
[] Yes (Go to #3)
[] No (Deny)
3. Is the dose requested less than or equal to (\leq) 0.8mg per day?
[] Yes (Approve – 365 days)
[] No (Deny)



**Desmopressin
Oral**
Clinical Criteria Logic Diagram





Desmopressin
Oral
Clinical Criteria Supporting Tables

| Step 1 (diagnosis of moderate to severe renal impairment) Required diagnosis: 1 Look back timeframe: 365 days | |
|--|--|
| ICD-10 Code | Description |
| I120 | HYPERTENSIVE CHRONIC KIDNEY DISEASE WITH STAGE 5 CHRONIC KIDNEY DISEASE OR END STAGE RENAL DISEASE |
| I129 | HYPERTENSIVE CHRONIC KIDNEY DISEASE WITH STAGE 1 THROUGH STAGE 4 CHRONIC KIDNEY DISEASE, OR UNSPECIFIED CHRONIC KIDNEY DISEASE |
| N010 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH MINOR GLOMERULAR ABNORMALITY |
| N011 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH FOCAL AND SEGMENTAL GLOMERULAR LESIONS |
| N012 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE MEMBRANOUS GLOMERULONEPHRITIS |
| N013 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS |
| N014 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE ENDOCAPILLARY PROLIFERATIVE GLOMERULONEPHRITIS |
| N015 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE MESANGIOPROLIFERATIVE GLOMERULONEPHRITIS |
| N016 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DENSE DEPOSIT DISEASE |
| N017 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE CRESCENTIC GLOMERULONEPHRITIS |
| N018 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH OTHER MORPHOLOGIC CHANGES |
| N019 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH UNSPECIFIED MORPHOLOGIC CHANGES |
| N038 | CHRONIC NEPHRITIC SYNDROME WITH OTHER MORPHOLOGIC CHANGES |
| N059 | UNSPECIFIED NEPHRITIC SYNDROME WITH UNSPECIFIED MORPHOLOGIC CHANGES |
| N1830 | CHRONIC KIDNEY DISEASE, STAGE 3 UNSPECIFIED |
| N1831 | CHRONIC KIDNEY DISEASE, STAGE 3A |
| N1832 | CHRONIC KIDNEY DISEASE, STAGE 3B |
| N184 | CHRONIC KIDNEY DISEASE, STAGE 4 (SEVERE) |
| N185 | CHRONIC KIDNEY DISEASE, STAGE 5 |
| N186 | END STAGE RENAL DISEASE |
| N189 | CHRONIC KIDNEY DISEASE, UNSPECIFIED |

Step 1 (diagnosis of moderate to severe renal impairment)**Required diagnosis: 1****Look back timeframe: 365 days**

| ICD-10 Code | Description |
|-------------|--|
| N261 | ATROPHY OF KIDNEY (TERMINAL) |
| N269 | RENAL SCLEROSIS, UNSPECIFIED |
| Z4901 | ENCOUNTER FOR FITTING AND ADJUSTMENT OF EXTRACORPOREAL DIALYSIS CATHETER |
| Z4902 | ENCOUNTER FOR FITTING AND ADJUSTMENT OF PERITONEAL DIALYSIS CATHETER |
| Z4931 | ENCOUNTER FOR ADEQUACY TESTING FOR HEMODIALYSIS |
| Z4932 | ENCOUNTER FOR ADEQUACY TESTING FOR PERITONEAL DIALYSIS |
| Z992 | DEPENDENCE ON RENAL DIALYSIS |

Step 2 (diagnosis of primary nocturnal enuresis or diabetes insipidus)**Required diagnosis: 1****Look back timeframe: 730 days**

| ICD-10 Code | Description |
|-------------|--|
| E871 | HYPO-OSMOLALITY AND HYponatremia |
| E232 | DIABETES INSIPIDUS |
| N393 | STRESS INCONTINENCE (FEMALE) (MALE) |
| N3941 | URGE INCONTINENCE |
| N3942 | INCONTINENCE WITHOUT SENSORY AWARENESS |
| N3943 | POST-VOID DRIBBLING |
| N3944 | NOCTURNAL ENURESIS |
| N3945 | CONTINUOUS LEAKAGE |
| N3946 | MIXED INCONTINENCE |
| N39490 | OVERFLOW INCONTINENCE |
| N39498 | OTHER SPECIFIED URINARY INCONTINENCE |
| R32 | UNSPECIFIED URINARY INCONTINENCE |
| R351 | NOCTURIA |
| R3581 | NOCTURNAL POLYURIA |



**Desmopressin
Injectable**
Drugs Requiring Prior Authorization

The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.

| Drugs Requiring Prior Authorization | |
|--|------------|
| Label Name | GCN |
| DDAVP 4 MCG/ML AMPUL | 10860 |
| DDAVP 4 MCG/ML VIAL | 10260 |
| DESMOPRESSIN AC 4 MCG/ML VL | 10260 |




**Desmopressin
Injectable
Clinical Criteria Logic**

1. Does the client have a diagnosis of **moderate to severe renal impairment** in the last 365 days?
[] Yes (Deny)
[] No (Go to #2)
2. Does the client have a diagnosis of **diabetes insipidus, hemophilia, or Von Willebrand's disease** in the last 730 days?
[] Yes (Go to #4)
[] No (Go to #3)
3. Does the client have a history of an **anti-hemophilic factors agent** in the last 730 days?
[] Yes (Go to #4)
[] No (Deny)
4. Is the dose requested less than or equal to (\leq) 1 ml per day?
[] Yes (Approve - 365 days)
[] No (Deny)



**Desmopressin
Injectable**
Clinical Criteria Logic Diagram





**Desmopressin
Injectable**
Clinical Criteria Supporting Tables

| Step 1 (diagnosis of moderate to severe renal impairment) Required diagnosis: 1 Look back timeframe: 365 days | |
|--|--|
| ICD-10 | Description |
| I120 | HYPERTENSIVE CHRONIC KIDNEY DISEASE WITH STAGE 5 CHRONIC KIDNEY DISEASE OR END STAGE RENAL DISEASE |
| I129 | HYPERTENSIVE CHRONIC KIDNEY DISEASE WITH STAGE 1 THROUGH STAGE 4 CHRONIC KIDNEY DISEASE, OR UNSPECIFIED CHRONIC KIDNEY DISEASE |
| N010 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH MINOR GLOMERULAR ABNORMALITY |
| N011 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH FOCAL AND SEGMENTAL GLOMERULAR LESIONS |
| N012 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE MEMBRANOUS GLOMERULONEPHRITIS |
| N013 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS |
| N014 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE ENDOCAPILLARY PROLIFERATIVE GLOMERULONEPHRITIS |
| N015 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE MESANGIOPROLIFERATIVE GLOMERULONEPHRITIS |
| N016 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DENSE DEPOSIT DISEASE |
| N017 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH DIFFUSE CRESCENTIC GLOMERULONEPHRITIS |
| N018 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH OTHER MORPHOLOGIC CHANGES |
| N019 | RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME WITH UNSPECIFIED MORPHOLOGIC CHANGES |
| N038 | CHRONIC NEPHRITIC SYNDROME WITH OTHER MORPHOLOGIC CHANGES |
| N059 | UNSPECIFIED NEPHRITIC SYNDROME WITH UNSPECIFIED MORPHOLOGIC CHANGES |
| N1830 | CHRONIC KIDNEY DISEASE, STAGE 3 UNSPECIFIED |
| N1831 | CHRONIC KIDNEY DISEASE, STAGE 3A |
| N1832 | CHRONIC KIDNEY DISEASE, STAGE 3B |
| N184 | CHRONIC KIDNEY DISEASE, STAGE 4 (SEVERE) |
| N185 | CHRONIC KIDNEY DISEASE, STAGE 5 |
| N186 | END STAGE RENAL DISEASE |
| N189 | CHRONIC KIDNEY DISEASE, UNSPECIFIED |

| Step 1 (diagnosis of moderate to severe renal impairment) Required diagnosis: 1 Look back timeframe: 365 days | |
|--|------------------------------|
| N261 | ATROPHY OF KIDNEY (TERMINAL) |
| N269 | RENAL SCLEROSIS, UNSPECIFIED |

| Step 2 (diagnosis of diabetes insipidus, hemophilia, or Von Willebrand's disease) Required diagnosis: 1 Look back timeframe: 730 days | |
|--|-----------------------------------|
| ICD-10 Code | Description |
| D66 | HEREDITARY FACTOR VIII DEFICIENCY |
| D680 | VON WILLEBRAND'S DISEASE |
| E232 | DIABETES INSIPIDUS |

| Step 3 (history of an anti-hemophilic factors agent) Required quantity: 1 Look back timeframe: 730 days | |
|--|------------|
| Label Name | GCN |
| ADVATE 1,201-1,800 UNITS VIAL | 98830 |
| ADVATE 1,801-2,400 UNITS VIAL | 98764 |
| ADVATE 2,401-3,600 UNITS VIAL | 98634 |
| ADVATE 200-400 UNITS VIAL | 98833 |
| ADVATE 3,601-4,800 UNITS VIAL | 32723 |
| ADVATE 401-800 UNITS VIAL | 98831 |
| ADVATE 801-1,200 UNITS VIAL | 98832 |
| ADYNOVATE 1,251-2,500 UNIT VIAL | 40213 |
| ADYNOVATE 1,500 UNIT VIAL | 43013 |
| ADYNOVATE 200-400 UNIT VIAL | 40207 |
| ADYNOVATE 3,000 UNIT VIAL | 43353 |
| ADYNOVATE 401-800 UNIT VIAL | 40208 |
| ADYNOVATE 750 UNIT VIAL | 43009 |
| ADYNOVATE 801-1,250 UNIT VIAL | 40209 |
| AFSTYLA 1,000 UNIT VIAL | 41501 |
| AFSTYLA 2,000 UNIT VIAL | 41502 |
| AFSTYLA 250 UNIT VIAL | 41497 |
| AFSTYLA 3,000 UNIT VIAL | 41503 |
| AFSTYLA 500 UNIT VIAL | 41499 |
| ALPHANATE 1,000-400 UNIT VIAL | 27334 |
| ALPHANATE 1,500-600 UNIT VIAL | 27335 |

| Step 3 (history of an anti-hemophilic factors agent) | |
|---|------------|
| Required quantity: 1 | |
| Look back timeframe: 730 days | |
| Label Name | GCN |
| ALPHANATE 2,000-800 UNIT VIAL | 37015 |
| ALPHANATE 250-100 UNIT VIAL | 27332 |
| ALPHANATE 500-200 UNIT VIAL | 27333 |
| ALPHANINE SD 500 UNIT VIAL | 91671 |
| ALPHANINE SD 1,000 UNIT VIAL | 91672 |
| ALPHANINE SD 1,500 UNIT VIAL | 21647 |
| ALPROLIX 500 UNIT NOMINAL | 36333 |
| ALPROLIX 1,000 UNIT NOMINAL | 36334 |
| ALPROLIX 2,000 UNIT NOMINAL | 36335 |
| ALPROLIX 3,000 UNIT NOMINAL | 36336 |
| ALPROLIX 250 UNIT NOMINAL | 40816 |
| ALPROLIX 4,000 UNIT NOMINAL | 42556 |
| AMICAR 500 MG TABLET | 25590 |
| AMICAR 1,000 MG TABLET | 23444 |
| AMICAR 0.25 GM/ML ORAL SOLN | 25580 |
| BENEFIX 250 UNIT RANGE | 34868 |
| BENEFIX 500 UNIT RANGE | 34869 |
| BENEFIX 1,000 UNIT RANGE | 34873 |
| BENEFIX 2,000 UNIT RANGE | 34874 |
| BENEFIX 3,000 UNIT RANGE | 34875 |
| CORIFACT KIT | 29584 |
| ELOCTATE 1,000 UNIT NOMINAL | 36663 |
| ELOCTATE 1,500 UNIT NOMINAL | 36664 |
| ELOCTATE 2,000 UNIT NOMINAL | 36665 |
| ELOCTATE 250 UNIT NOMINAL | 36657 |
| ELOCTATE 3,000 UNIT NOMINAL | 36666 |
| ELOCTATE 4,000 UNIT NOMINAL | 43115 |
| ELOCTATE 5,000 UNIT NOMINAL | 43116 |
| ELOCTATE 500 UNIT NOMINAL | 36658 |
| ELOCTATE 6,000 UNIT NOMINAL | 43114 |
| ELOCTATE 750 UNIT NOMINAL | 36662 |
| FEIBA NF 500 UNIT (NOMINAL) | 23816 |
| FEIBA NF 1,000 UNIT (NOMINAL) | 23815 |
| FEIBA NF 2,500 UNIT (NOMINAL) | 26335 |
| HELIXATE FS 1,000 UNIT VIAL | 98832 |
| HELIXATE FS 2,000 UNIT VIAL | 98764 |

| Step 3 (history of an anti-hemophilic factors agent) | |
|---|------------|
| Required quantity: 1 | |
| Look back timeframe: 730 days | |
| Label Name | GCN |
| HELIXATE FS 250 UNIT VIAL | 98833 |
| HELIXATE FS 3,000 UNITS VIAL | 98634 |
| HELIXATE FS 500 UNIT VIAL | 98831 |
| HEMLIBRA 30 MG/ML VIAL | 44104 |
| HEMLIBRA 60 MG/0.4 ML VIAL | 44105 |
| HEMLIBRA 105 MG/0.7 ML VIAL | 44106 |
| HEMLIBRA 150 MG/ML VIAL | 44107 |
| HEMOFIL M 1,000 UNIT NOMINAL | 30193 |
| HEMOFIL M 1,700 UNIT NOMINAL | 30194 |
| HEMOFIL M 250 UNIT NOMINAL | 26777 |
| HEMOFIL M 500 UNIT NOMINAL | 26778 |
| HUMATE-P 1,200 UNIT VWF:RCO | 26451 |
| HUMATE-P 2,400 UNIT VWF:RCO | 26450 |
| HUMATE-P 600 UNIT VWF:RCO | 26449 |
| IDEVION 250 UNIT VIAL | 40749 |
| IDEVION 500 UNIT VIAL | 40751 |
| IDEVION 1,000 UNIT VIAL | 40752 |
| IDEVION 2,000 UNIT VIAL | 40753 |
| IDEVION 3,500 UNIT VIAL | 44859 |
| KOATE 1,000 UNIT VIAL | 25129 |
| KOATE 250 UNIT VIAL | 25151 |
| KOATE 500 UNIT VIAL | 25132 |
| KOGENATE FS 1,000 UNITS VIAL | 98832 |
| KOGENATE FS 2,000 UNITS VIAL | 98764 |
| KOGENATE FS 250 UNIT VIAL | 98833 |
| KOGENATE FS 3,000 UNITS VIAL | 98634 |
| KOGENATE FS 500 UNIT VIAL | 98831 |
| KOVALTRY 1,000 UNIT KIT | 98832 |
| KOVALTRY 2,000 UNIT KIT | 98764 |
| KOVALTRY 250 UNIT KIT | 98833 |
| KOVALTRY 3,000 UNIT KIT | 98634 |
| KOVALTRY 500 UNIT KIT | 98831 |
| LYSTEDA 650 MG TABLET | 28578 |
| MONOCLATE-P 1,000 UNIT KIT | 25129 |
| MONOCLATE-P 1,500 UNIT KIT | 25131 |
| NOVOEIGHT 1,000 UNIT VIAL | 37395 |

| Step 3 (history of an anti-hemophilic factors agent) | |
|---|------------|
| Required quantity: 1 | |
| Look back timeframe: 730 days | |
| Label Name | GCN |
| NOVOEIGHT 1,500 UNIT VIAL | 37396 |
| NOVOEIGHT 2,000 UNIT VIAL | 37397 |
| NOVOEIGHT 250 UNIT VIAL | 37393 |
| NOVOEIGHT 3,000 UNIT VIAL | 37398 |
| NOVOEIGHT 500 UNIT VIAL | 37394 |
| NUWIQ 1,000 UNIT VIAL PACK | 38025 |
| NUWIQ 2,000 UNIT VIAL PACK | 38027 |
| NUWIQ 2,500 UNIT VIAL PACK | 43791 |
| NUWIQ 250 UNIT VIAL PACK | 38023 |
| NUWIQ 3,000 UNIT VIAL PACK | 43792 |
| NUWIQ 4,000 UNIT VIAL PACK | 43793 |
| NUWIQ 500 UNIT VIAL PACK | 38024 |
| NOVOSEVEN RT 1MG VIAL | 99696 |
| NOVOSEVEN RT 2MG VIAL | 99697 |
| NOVOSEVEN RT 5MG VIAL | 99698 |
| NOVOSEVEN RT 8MG VIAL | 29034 |
| REBINYN 1,000 UNIT VIAL | 43483 |
| REBINYN 2,000 UNIT VIAL | 43484 |
| REBINYN 500 UNIT VIAL | 43442 |
| RECOMBINATE 1,241-2,400 UNIT V | 27008 |
| RECOMBINATE 1,801-2,400 UNIT V | 26818 |
| RECOMBINATE 220-400 UNIT VIAL | 25123 |
| RECOMBINATE 401-800 UNIT VIAL | 25125 |
| RECOMBINATE 801-1,240 UNIT VL | 25124 |
| TRETEN 2,500 UNIT VIAL | 35833 |
| VONVENDI 650 UNIT VIAL | 40278 |
| VONVENDI 1,300 UNIT VIAL | 40279 |
| WILATE 1,000-1,000 UNIT KIT | 32239 |
| WILATE 500-500 UNIT KIT | 32238 |
| XYNTHA 1,000 UNIT KIT | 99872 |
| XYNTHA 2,000 UNIT KIT | 99873 |
| XYNTHA 250 UNIT KIT | 99870 |
| XYNTHA 500 UNIT KIT | 99871 |
| XYNTHA SOLOFUSE 1,000 UNIT KIT | 30439 |
| XYNTHA SOLOFUSE 2,000 UNIT KIT | 30441 |
| XYNTHA SOLOFUSE 250 UNIT KIT | 31205 |

Step 3 (history of an anti-hemophilic factors agent)**Required quantity: 1****Look back timeframe: 730 days**

| Label Name | GCN |
|--------------------------------|-------|
| XYNTHA SOLOFUSE 3,000 UNIT KIT | 29387 |
| XYNTHA SOLOFUSE 500 UNIT KIT | 31206 |



Desmopressin

Clinical Criteria References

1. Food and Drug Administration (FDA). MedWatch. Available at: <http://www.fda.gov/medwatch/safety/2007/safety07.htm#Desmopressin>. Accessed on March 3, 2008.
2. Desmopressin acetate (DDAVP®) [official prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S., LLC. Available at: <http://www.fda.gov/cder/foi/label/2007/017922s038,018938s027,019955s0131bl.pdf>. Accessed on February 27, 2008.
3. 2015 ICD-10-CM Diagnosis Codes. 2015. Available at www.icd10data.com. Accessed on April 3, 2015.
4. American Medical Association data files. 2015 ICD-10-CM Diagnosis Codes. Available at www.commerce.ama-assn.org.
5. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; 2022. Available at www.clinicalpharmacology.com. Accessed on October 18, 2022.
6. Micromedex [online database]. Available at www.micromedexsolutions.com. Accessed on October 18, 2022.
7. Stimate Prescribing Information. King of Prussia, PA. CSL Behring LLC. June 2013.
8. Tu ND, Baskin LS. Nocturnal Enuresis in Children: Management. In: UpToDate, Drutz JE, Voigt RG (Ed), UpToDate, Waltham, MA, 2022.
9. Bichet DG. Treatment of Central Diabetes Insipidus. In: UpToDate, Sterns RH, Emmett M, Wolfsdorf JI (Ed), UpToDate, Waltham, MA, 2022.
10. Nevéus T, Fonseca E, Franco I, et al. Management and treatment of nocturnal enuresis—an updated standardization document from the International Children's Continence Society. *J Pediatr Urol* 2022; 16:10.

Publication History

The Publication History records the publication iterations and revisions to this document. Notes for the *most current revision* are also provided in the **Revision Notes** on the first page of this document.

| Publication Date | Notes |
|------------------|--|
| 05/24/2012 | Initial publication and posting to website |
| 10/25/2013 | Changed "DM" to "diabetes insipidus" in step 3 of the clinical edit criteria logic and the logic diagram for Desmopressin – Oral |
| 04/03/2015 | Updated to include ICD-10s |
| 05/08/2017 | Annual review by staff Updated Table 4, page 15 Updated References, page 17 |
| 03/27/2019 | Updated to include formulary statement (The listed GCNS may not be an indication of TX Medicaid Formulary coverage. To learn the current formulary coverage, visit TxVendorDrug.com/formulary/formulary-search.) on each 'Drug Requiring PA' table |
| 12/21/2020 | Removed check for hyponatremia from criteria logic and logic diagram |
| 10/18/2022 | Annual review by staff Added ICD-10 codes R351 (nocturia) and R3581 (nocturnal polyuria) to Table 2, desmopressin oral agents Added GCNs for Alphanine vials (91671, 91672, 21647), Alprolix (36333, 36334, 36335, 36336, 40816, 42556), Amicar (25590, 23444, 25580), Benefix (34868, 34869, 34873, 34874, 34875), Corifact (29584), Hemlibra (44104, 44105, 44106, 44107), Idelvion (40749, 40751, 40752, 40753, 44859), Lysteda (28578), Rebinyn (43483, 43484, 43442), Tretten (35833), and Vonvendi (40278, 40279) to Table 3 Updated severe renal impairment to moderate to severe renal impairment for question 1 for oral and injectable desmopressin Updated references |
| 02/01/2023 | Updated ICD-10 codes for dialysis in supporting table 1 for desmopressin oral agents |